Resolution Therapeutics to showcase key preclinical data on its Regenerative Macrophage Therapy (RMT) RTX001 in oral presentation at ASGCT 2026

RTX001 is an engineered Regenerative Macrophage Therapy for end-stage liver disease (ESLD) with anti-inflammatory and anti-fibrotic properties These new preclinical data demonstrate RTX001’s pharmacology, safety, tolerability, and efficacy in mouse models, with reduced fibrosis and inflammation observed Results confirm RTX001’s positive preclinical safety and therapeutic profile ahead of interim results from Resolution’s Phase I/II EMERALD clinical trial, expected H2 2026   Edinburgh and London, UK, 12 May 2026 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, will present key preclinical data today on its Regenerative Macrophage Therapy RTX001 in an oral presentation at the ASGCT Annual Meeting, being held from 11-15 May, 2026, in Boston, Massachusetts, US.   The presentation will outline Resolution’s strategy for testing the safety, biodistribution and pharmacology of RTX001, the Company’s engineered RMT. The preclinical data show RTX001 has a strong pharmacological and pharmacokinetic profile, is safe in mouse models, and is effective at reducing liver enzymes, inflammation, and fibrosis.   These data further establish RTX001’s positive preclinical safety and therapeutic profile, as Resolution awaits interim results from its Phase I/II EMERALD clinical trial in patients with ESLD, which are expected in the second half of 2026.   Lara Campana, Scientific Co-Founder and SVP, Head of Research and Translational Science at Resolution Therapeutics, said: “We are thrilled to have been selected for an oral presentation at this year’s ASGCT meeting. These pharmacology data offer the first glimpse into the dual local and systemic anti-inflammatory effects of RTX001. This is a highly promising result as patients with end-stage liver disease often experience peaks of systemic inflammation when suffering a liver decompensation event.”   Amir Hefni, Chief Executive Officer of Resolution Therapeutics, said: “These data reinforce our conviction in the enormous potential of Regenerative Macrophage Therapy in fibrotic and inflammatory conditions, and in RTX001’s ability to revolutionise the treatment landscape for end-stage liver disease, a debilitating affliction with a huge unmet need.”   Details of the oral presentation are as follows:   Presentation title: Preclinical development of an engineered regenerative macrophage therapy for end-stage liver disease Presenter: Lara Campana, Resolution Therapeutics Presentation session: Novel T-cell and myeloid strategies Session date and time: 12 May 2026, 3.30pm – 5.00pm EDT Location: MCEC Room 206AB (Level 2) Presentation Time: 4.45pm – 5.00pm EDT   The ASGCT interactive programme can be found here. Resolution Therapeutics’ abstract (ID 113, pages 204-205) can be found here.

The release as fetched from its publisher. resolution-tx.com ↗